Body mass index may determine which blood pressure treatments work best

December 05, 2012

"These findings could change the way high blood pressure (hypertension) is treated and should be of practical help to clinicians in selecting the type of combination treatment most likely to benefit individual patients"*, says Michael Weber from the State University of New York's Downstate Medical Center who led the research. "Importantly, they suggest that hypertension in obese and lean patients is probably mediated by different forms of underlying disease processes."

Weber and colleagues conducted a subanalysis of the international ACCOMPLISH trial that compared the impact of two single-pill drug combinations**--benazepril (ACE inhibitor) plus the diuretic hydrochlorothiazide, and benazepril plus amlodipine (calcium channel blocker)-- on the long-term health of people with high blood pressure at high risk of heart disease.

The researchers grouped 11482 participants according to three body mass index categories (normal weight, overweight, and obese) to assess the effects of body mass index and different treatment regimens on heart-related events (cardiovascular deaths, hearts attacks, and strokes).

The analysis showed that in people assigned to the diuretic combination a normal BMI was associated with significantly worse outcomes--a 68% higher event rate--than a high BMI.

In contrast, the benazepril and amlodipine combination was equally effective across all weight categories. What is more, compared with the diuretic regimen, the combination of benazepril and amlodipine significantly reduced heart-related events in normal weight (difference 43%) and overweight (24%) individuals.

Both treatments worked as well in obese people, with no major difference in outcomes recorded between the two regimens.

Weber speculates that, "Higher cardiovascular event rates in lean patients reported in hypertension clinical trials might have reflected the types of antihypertensive treatments that were used. Diuretic-based regimens seem to be a reasonable choice in obese patients in whom excess volume provides a rationale for this type of treatment, but thiazides are clearly less protective against cardiovascular events in patients who are lean."

However, he cautions, "Our observations might not be fully generalisable to all types of treatments...since they were driven predominantly by findings in one (the diuretic-based) of our two treatment groups."*

Contrary to the conclusion of Weber and colleagues, Franz Messerli from Columbia University College of Physicians and Surgeons in New York and Sripal Bangalore from New York University School of Medicine, New York argue in a linked Comment that diuretic-based regimens are not a suitable choice in obese patients. They conclude, "If the indication is hypertension, amlodipine-based treatment should be used irrespective of body size. Conversely, if the indication is prevention or treatment of left-ventricular dysfunction, a diuretic based regimen should be used, again irrespective of body size. This strategy relegates diuretics to third-line agents for treatment of hypertension, except in patients at risk of heart failure--a position recognised in the latest UK guidelines."
-end-
Notes to Editors:

*Quotes direct from author and cannot be found in text of Article.

**ACE inhibitors reduce blood pressure by preventing the conversion of the hormone angiotensin I into angiotensin II, and thus averting the narrowing of blood vessels caused by angiotensin II. Diuretics work by clearing the body of excess fluid and sodium, while calcium channel blockers relax blood vessels by slowing the flow of calcium into arterial smooth muscle cells.

Lancet

Related Hypertension Articles from Brightsurf:

Risk of target organ damage in patients with masked hypertension versus sustained hypertension
In a new publication from Cardiovascular Innovations and Applications; DOI https://doi.org/10.15212/CVIA.2019.1261, Yue Wu, Guoyue Zhang, Rong Hu and Jianlin Du from The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China consider the risk of target organ damage in patients with masked hypertension versus sustained hypertension.

Overactive enzyme causes hereditary hypertension
After more than 40 years, several teams at the MDC and ECRC have now made a breakthrough discovery with the help of two animal models: they have proven that an altered gene encoding the enzyme PDE3A causes an inherited form of high blood pressure.

Diagnosing hypertension in children
Study results call into question the utility of testing blood pressure load--the proportion of elevated blood pressure readings detected over 24 hours--for diagnosing hypertension in children.

When the best treatment for hypertension is to wait
A new study concluded that a physician's decision not to intensify hypertension treatment is often a contextually appropriate choice.

Treatment of hypertension induced albuminuria
Patients with albuminuria will usually need more than one drug to achieve blood pressure control, particularly if the aim is also to reduce albuminuria.

Diagnosing and treating resistant hypertension
Resistant blood pressure affects 12 percent to 15 percent of people currently being treated for high blood pressure.

Dementia can be caused by hypertension
A new study in Cardiovascular Research indicates that patients with high blood pressure are at a higher risk of developing dementia.

Hormone imbalance causes treatment-resistant hypertension
British researchers have discovered a hormone imbalance that explains why it is very difficult to control blood pressure in around 10 per cent of hypertension patients.

Breastfeeding reduces hypertension risk
A study published in the American Journal of Hypertension indicates that women who breastfeed more children, and for longer periods of time, are less likely to suffer from hypertension after they reach menopause.

Lung cancer triggers pulmonary hypertension
Nearly half of all advanced-stage lung cancer patients develop arterial pulmonary hypertension.

Read More: Hypertension News and Hypertension Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.